Package Leaflet: Information for the User
Rapamune 0.5mg film-coated tablets
Rapamune 1 mg film-coated tablets
Rapamune 2mg film-coated tablets
sirolimus
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants. It helps to control your body's immune system after you have received a kidney transplant.
Rapamune is used in adults to prevent the rejection of transplanted kidneys and is normally used in combination with other immunosuppressive medicines called corticosteroids, and initially (for the first 2 to 3 months) with ciclosporin.
Do not take Rapamune:
Warnings and precautions
Consult your doctor or pharmacist before you start taking Rapamune.
Your doctor will perform tests to monitor your blood levels of Rapamune. Your doctor will also perform tests to monitor your kidney function, to measure your lipid (cholesterol and/or triglyceride) levels in your blood, and possibly your liver function, during treatment with Rapamune.
Exposure to sunlight and UV light should be limited by covering your skin with clothing and using a sunscreen with a high protection factor, due to the increased risk of skin cancer.
Children and adolescents
Experience with the use of Rapamune in children and adolescents under 18 years of age is limited. The use of Rapamune in this population is not recommended.
Taking Rapamune with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines may interfere with the action of Rapamune and you may need a dose adjustment. In particular, you should tell your doctor or pharmacist if you are taking any of the following medicines:
Live vaccines should be avoided during treatment with Rapamune. Before vaccination, inform your doctor or pharmacist that you are receiving Rapamune.
The use of Rapamune may lead to an increase in your cholesterol and triglyceride levels in your blood (blood fats) which may require treatment. Medicines known as "statins" and "fibrates" used to treat high cholesterol and triglycerides, have been associated with an increased risk of muscle fibre breakdown (rhabdomyolysis). Tell your doctor if you are taking medicines to lower your blood fats.
The combined use of Rapamune and angiotensin-converting enzyme (ACE) inhibitors (a type of medicine used to lower blood pressure) may cause allergic reactions. Inform your doctor if you are taking these medicines.
Taking Rapamune with food and drink
Always take Rapamune in the same way, with or without food. If you prefer to take Rapamune with food, you should always take it with food. If you prefer to take Rapamune without food, you should always take it without food. Food can affect the amount of medicine that gets into your blood and by taking your medicine in the same way, the levels of Rapamune in your blood will be more even.
Do not take Rapamune with grapefruit juice.
Pregnancy, breast-feeding and fertility
Rapamune should not be used during pregnancy unless clearly necessary. You should use effective contraception during treatment with Rapamune and for 12 weeks after stopping treatment. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known if Rapamune passes into breast milk. Patients who take Rapamune should not breast-feed.
A reduction in sperm count has been associated with the use of Rapamune, which usually returns to normal after stopping treatment.
Driving and using machines
Although it is not expected that treatment with Rapamune will affect your ability to drive, if you are in any doubt, consult your doctor.
Rapamune contains lactose and sucrose
Rapamune contains 86.4 mg of lactose and up to 215.8 mg of sucrose. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Your doctor will decide the exact dose of Rapamune that you should take and how often you should take it. Always follow your doctor's instructions exactly and never change the dose yourself.
Your doctor will give you an initial dose of 6 mg as soon as possible after your kidney transplant operation. After this, you will need to take 2 mg of Rapamune every day until your doctor tells you otherwise. Your dose will be adjusted depending on your blood levels of Rapamune. Your doctor will need to perform blood tests to measure the levels of Rapamune in your blood.
If you are also taking ciclosporin, you should space the taking of the two medicines by approximately 4 hours.
It is recommended to use Rapamune in combination with ciclosporin and corticosteroids. After 3 months, your doctor may stop Rapamune or ciclosporin, as it is not recommended to take these medicines together after this time.
Rapamune is for oral use only. Do not crush, chew or break the tablets. Inform your doctor if you have difficulty taking the tablet.
You should not take several 0.5 mg Rapamune tablets as a substitute for the 1 mg and 2 mg tablets as they are not directly interchangeable.
Rapamune should be taken with food, or without food, but always in the same way.
If you take more Rapamune than you should
If you have taken more medicine than you should, contact your doctor or go to the casualty department of your nearest hospital immediately. Always take the labelled blister pack with you, even if it is empty.
If you forget to take Rapamune
If you forget to take Rapamune, take it as soon as you remember, but not within 4 hours of your ciclosporin dose. After this, continue to take your medicine as normal. Do not take a double dose to make up for a forgotten dose, and always take Rapamune and ciclosporin with a difference of approximately 4 hours. If you have forgotten to take a dose of Rapamune altogether, you should inform your doctor.
If you stop taking Rapamune
Do not stop taking Rapamune unless your doctor tells you to, as you may be at risk of losing your transplant.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
You should see your doctor immediatelyif you experience symptoms such as swelling of the face, tongue and/or the back of the throat (pharynx) and/or difficulty breathing (angioedema), or skin peeling (exfoliative dermatitis). These could be symptoms of a severe allergic reaction.
Kidney damage with low blood cell counts (thrombocytopenic purpura/hemolytic uremic syndrome)
When taken with medicines called calcineurin inhibitors (ciclosporin or tacrolimus), Rapamune may increase the risk of a condition that combines kidney damage with low blood cell counts and skin rash. If you experience symptoms such as bruising, skin rash, changes in urine, mood changes or any other symptom that you consider serious, unusual or prolonged, contact your doctor.
Infections
Rapamune reduces your body's defences to prevent it from rejecting the transplanted organ. As a result, your body will not be as good at fighting infections as it used to be. Therefore, if you are taking Rapamune, you may catch more infections than usual, such as infections of the skin, mouth, stomach and gut, lungs and urinary tract (see list below). You should contact your doctor if you experience symptoms that you consider serious, unusual or prolonged.
Frequency of side effects
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known: cannot be estimated from the available data
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after “EXP”. The expiry date refers to the last day of that month.
Do not store above 25°C.
Store the blister in the outer carton in order to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Rapamune Composition
The active ingredient is sirolimus.
Each Rapamune 0.5 mg coated tablet contains 0.5 mg of sirolimus.
Each Rapamune 1 mg coated tablet contains 1 mg of sirolimus.
Each Rapamune 2 mg coated tablet contains 2 mg of sirolimus.
The other components are:
Core of the tablets: lactose monohydrate, macrogol, magnesium stearate, talc
Coating of the tablets: macrogol, glycerol monooleate, pharmaceutical varnish, calcium sulfate, microcrystalline cellulose, sucrose, titanium dioxide, poloxamer 188, α-tocopherol, povidone, carnauba wax, printing ink (gum lacquer, red iron oxide, propylene glycol, ammonium hydroxide, simethicone). The 0.5 mg and 2 mg tablets also containyellow iron oxide (E172) and brown iron oxide (E172).
Product Appearance and Container Content
Rapamune 0.5 mg is presented in the form of triangular, light brown, coated tablets, engraved on one face with “RAPAMUNE 0.5 mg”.
Rapamune 1 mg is presented in the form of triangular, white, coated tablets, engraved on one face with “RAPAMUNE 1 mg”.
Rapamune 2 mg is presented in the form of triangular, yellow-beige, coated tablets, engraved on one face with “RAPAMUNE 2 mg”.
The tablets are packaged in blisters of 30 and 100 tablets. Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing AuthorizationHolder: Pfizer Limited Ramsgate Road Sandwich Kent, CT13 9NJ United Kingdom | Manufacturer: Pfizer Ireland Pharmaceuticals Unlimited Company Little Connell Newbridge Co. Kildare Ireland Pfizer Manufacturing Deutschland GmbH Mooswaldallee 1 79108 Freiburg Im Breisgau Germany |
For further information on this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/BelgienLuxembourg/Luxemburg Pfizer NV/SA Tel: +32 (0)2 554 62 11 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +3705 2514000 |
България Пфайзер България ЕООД, София Тел: +359 2 970 4333 | Magyarország Pfizer Kft. Tel: +36 1 488 3700 |
Česká Republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Malta Vivian Corporation Ltd. Tel: +35621 344610 |
Danmark Pfizer ApS Tlf: +45 44 201 100 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Deutschland Pfizer Pharma GmbH Tel: +49 (0)30 550055-51000 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
Ελλάδα PFIZER ΕΛΛΑΣ A.E.Τηλ.: +30 210 6785 800 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
España Pfizer, S.L. Tel:+34914909900 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
France Pfizer Tél: +33 (0) 1 58 07 34 40 | România Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 00 |
Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 777 | Slovenija Pfizer Luxembourg SARL, Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 400 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: +1800 633 363 (toll free) Tel: +44 (0)1304 616161 | Slovenská Republika Pfizer Luxembourg SARL, organizacná zložka Tel: + 421 2 3355 5500 |
Ísland Icepharma hf Tel: +354 540 8000 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Sverige Pfizer AB Tel: +46 (0)8 550 520 00 |
Κύπρος PFIZER ΕΛΛΑΣ Α.Ε. (Cyprus Branch) Tηλ.: +357 22 817690 | |
Latvija Pfizer Luxembourg SARL filiale Latvija Tel. +371 67035775 |
Date of Last Revision of this Leaflet: 01/2025.
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.